Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Avalo Therapeutics, Inc. AVTX

Healthcare  —  Biotechnology
15.47 (0.25) (1.59%) as of 25 Sep
Market cap
$843.1M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Avalo Therapeutics, Inc. (AVTX) Business Profile

Updated before January 2025

Company Overview

Avalo Therapeutics, Inc. (AVTX) is a clinical-stage biotechnology company dedicated to the development and commercialization of targeted therapeutics for immune-related diseases. Founded in 2011 and headquartered in Rockville, Maryland, Avalo Therapeutics has established itself as a key player in the biopharmaceutical industry. The company was initially known as Cerecor, Inc., but rebranded to Avalo Therapeutics in 2021 to better reflect its focus on immunology and rare diseases.

The leadership team at Avalo Therapeutics is composed of experienced professionals with extensive backgrounds in biotechnology and pharmaceuticals. The company is led by its CEO, Dr. Garry Neil, who brings decades of expertise in drug development and commercialization. Other key members of the leadership team include the Chief Financial Officer, Christopher Sullivan, and Chief Medical Officer, Dr. David Clark. Together, they drive Avalo’s mission to address unmet medical needs through innovative therapies.

Core Business Segments

Avalo Therapeutics focuses on developing therapies for immune-mediated diseases and rare conditions. Its core business segments include:

1. Immunology and Inflammation

Avalo’s primary focus is on developing treatments for immune-mediated diseases. The company’s lead product candidates in this segment include:

  • AVTX-002: A monoclonal antibody targeting LIGHT (a cytokine involved in immune system regulation). AVTX-002 is being developed for the treatment of severe inflammatory diseases, including acute respiratory distress syndrome (ARDS) and Crohn’s disease.
  • AVTX-007: A monoclonal antibody targeting IL-18, a cytokine implicated in inflammatory and autoimmune diseases. This candidate is being studied for conditions such as Still’s disease and hemophagocytic lymphohistiocytosis (HLH).

2. Rare Diseases

Avalo is also committed to addressing rare and orphan diseases. The company’s pipeline includes:

  • AVTX-803: A therapy for congenital disorders of glycosylation (CDGs), a group of rare genetic conditions that affect protein and lipid glycosylation.

3. Early-Stage Research

Avalo is actively exploring additional therapeutic areas through its early-stage research programs. These initiatives aim to expand the company’s pipeline and address other unmet medical needs.

Business Model

Avalo Therapeutics operates as a clinical-stage biotechnology company, meaning its primary focus is on research and development (R&D) rather than commercial product sales. The company’s business model revolves around:

  • Drug Development: Avalo invests heavily in R&D to advance its pipeline of targeted therapies. The company conducts preclinical studies, clinical trials, and regulatory submissions to bring its products to market.
  • Partnerships and Collaborations: Avalo collaborates with academic institutions, research organizations, and other biopharmaceutical companies to accelerate drug development and leverage external expertise.
  • Revenue Generation: While Avalo does not yet have commercialized products, it generates revenue through licensing agreements, milestone payments, and research grants.

Strategic Direction

Avalo Therapeutics has a clear strategic vision for the future, which includes:

  • Advancing Clinical Programs: The company is focused on progressing its lead candidates, AVTX-002 and AVTX-007, through clinical trials and obtaining regulatory approvals.
  • Expanding the Pipeline: Avalo aims to identify and develop additional therapeutic candidates, particularly in the areas of immunology and rare diseases.
  • Sustainability Goals: While not explicitly stated, Avalo is likely to adopt sustainable practices in its operations, including ethical sourcing of materials and minimizing environmental impact.
  • Global Expansion: The company plans to expand its presence in international markets, particularly in regions with high unmet medical needs.

Competitive Landscape

Avalo Therapeutics operates in a highly competitive industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Regeneron Pharmaceuticals: Known for its expertise in monoclonal antibodies and immunology.
  • Amgen: A leader in biotechnology with a strong focus on inflammation and rare diseases.
  • Vertex Pharmaceuticals: Specializes in rare diseases and has a robust pipeline of innovative therapies.
  • Smaller Biotech Firms: Companies like Allakos and ChemoCentryx also compete in the immunology and rare disease space.

Avalo differentiates itself through its targeted approach to immune-mediated diseases and its focus on rare conditions with high unmet needs.

Risk Factors

Like any clinical-stage biotech company, Avalo Therapeutics faces several risks, including:

  • Regulatory Risks: The success of Avalo’s pipeline depends on obtaining regulatory approvals, which can be uncertain and time-consuming.
  • Market Dependence: The company’s future revenue relies heavily on the successful commercialization of its lead candidates.
  • Supply Chain Disruptions: Avalo may face challenges in sourcing raw materials or manufacturing its products.
  • Financial Risks: As a pre-revenue company, Avalo depends on external funding and may face financial constraints if it cannot secure additional capital.
  • Competitive Pressure: The biotech industry is highly competitive, and Avalo must continuously innovate to maintain its position.

Recent Developments

Avalo Therapeutics has made significant progress in recent years, including:

  • Clinical Trial Advancements: The company has reported positive interim results for AVTX-002 in treating ARDS and continues to advance its clinical programs.
  • Pipeline Expansion: Avalo has initiated early-stage research programs to explore new therapeutic areas.
  • Corporate Restructuring: The company has streamlined its operations to focus on its core strengths in immunology and rare diseases.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of therapies for respiratory conditions, creating new opportunities for AVTX-002.

Investment Considerations

Investors considering Avalo Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: Avalo’s focus on targeted therapies for immune-mediated diseases and rare conditions positions it as a leader in these niches.
  • Experienced Leadership: The company’s management team has a proven track record in drug development and commercialization.
  • High Unmet Needs: Avalo’s therapies address conditions with limited treatment options, providing significant market potential.

Risks

  • Clinical and Regulatory Uncertainty: The success of Avalo’s pipeline is not guaranteed, and delays in clinical trials or regulatory approvals could impact the company’s prospects.
  • Financial Dependence: As a pre-revenue company, Avalo relies on external funding, which may not always be available.
  • Market Competition: The biotech industry is highly competitive, and Avalo faces challenges from both established players and emerging startups.

Conclusion

Avalo Therapeutics, Inc. is a promising clinical-stage biotechnology company with a strong focus on immune-mediated diseases and rare conditions. While the company faces significant risks, its innovative pipeline, experienced leadership, and commitment to addressing unmet medical needs position it for long-term success. As Avalo advances its clinical programs and expands its pipeline, it has the potential to become a key player in the biopharmaceutical industry.